Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

N Boku, M-H Ryu, K Kato, H C Chung, K Minashi, K-W Lee, H Cho, W K Kang, Y Komatsu, M Tsuda, K Yamaguchi, H Hara, S Fumita, M Azuma, L-T Chen, Y-K Kang, N Boku, M-H Ryu, K Kato, H C Chung, K Minashi, K-W Lee, H Cho, W K Kang, Y Komatsu, M Tsuda, K Yamaguchi, H Hara, S Fumita, M Azuma, L-T Chen, Y-K Kang

Abstract

Background: Nivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2. To further improve the therapeutic efficacy of first-line therapy, exploration of a nivolumab-chemotherapy combination is warranted. In part 1 (phase II) of ATTRACTION-4, the safety and efficacy of nivolumab combined with S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (CapeOX) as first-line therapy for unresectable advanced or recurrent human epidermal growth factor receptor 2 (HER2)-negative G/GEJ cancer were evaluated.

Patients and methods: Patients were randomized (1 : 1) to receive nivolumab (360 mg intravenously every 3 weeks) plus SOX (S-1, 40 mg/m2 orally twice daily for 14 days followed by 7 days off; oxaliplatin, 130 mg/m2 intravenously on day 1 every 3 weeks) or CapeOX (capecitabine, 1000 mg/m2 orally twice daily for 14 days followed by 7 days off; oxaliplatin, 130 mg/m2 intravenously on day 1 every 3 weeks) until disease progression, unacceptable toxicity, or consent withdrawal.

Results: Of 40 randomized patients, 39 (nivolumab plus SOX, 21; nivolumab plus CapeOX, 18) and 38 (21 and 17, respectively) comprised the safety and efficacy populations, respectively. Most frequent (>10%) grade 3/4 treatment-related adverse events were neutropenia (14.3%) in the nivolumab plus SOX group, and neutropenia (16.7%), anemia, peripheral sensory neuropathy, decreased appetite, type 1 diabetes mellitus, and nausea (11.1% each) in the nivolumab plus CapeOX group. No treatment-related death occurred. Objective response rate was 57.1% (95% confidence interval 34.0-78.2) with nivolumab plus SOX and 76.5% (50.1-93.2) with nivolumab plus CapeOX. Median overall survival was not reached (NR) in both groups. Median progression-free survival was 9.7 months (5.8-NR) and 10.6 months (5.6-12.5), respectively.

Conclusion: Nivolumab combined with SOX/CapeOX was well tolerated and demonstrated encouraging efficacy for unresectable advanced or recurrent HER2-negative G/GEJ cancer. ATTRACTION-4 has proceeded to part 2 (phase III) to compare nivolumab plus SOX/CapeOX versus placebo plus SOX/CapeOX.

Clinicaltrials.gov id: NCT02746796.

Keywords: S-1; capecitabine; gastric/gastroesophageal cancer; nivolumab; oxaliplatin; programmed death-1.

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

Figures

Figure 1.
Figure 1.
Kaplan–Meier curves for (A) overall survival and (B) progression-free survival (central assessment) (FAS population) CapeOX, capecitabine plus oxaliplatin; FAS, full analysis set; SOX, S-1 (tegafur–gimeracil–oteracil potassium) plus oxaliplatin.
Figure 2.
Figure 2.
(A) Best change from baseline in the sum of longest target lesion diameters in each patient receiving nivolumab plus SOX. (B) Best change from baseline in the sum of longest target lesion diameters in each patient receiving nivolumab plus CapeOX. (C) Percent change in sum of longest diameters of target lesion from baseline in each patient receiving nivolumab plus SOX. (D) Percent change in sum of longest diameters of target lesion from baseline in each patient receiving nivolumab plus CapeOX (central assessment) (FAS population). CapeOX, capecitabine plus oxaliplatin; FAS, full analysis set; PD-L1, programmed death-ligand 1; SOX, S-1 (tegafur–gimeracil–oteracil potassium) plus oxaliplatin.

References

    1. Ferlay J, Soerjomataram I, Ervik M. et al. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0. IARC CancerBase No. 11. International Agency for Research on Cancer; (16 November 2018, date last accessed).
    1. Ajani JA, D'Amico TA, Almhanna K. et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016; 14(10): 1286–1312.
    1. Smyth EC, Verheij M, Allum W. et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(Suppl 5): v38–v49.
    1. Okines AF, Norman AR, McCloud P. et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20(9): 1529–1534.
    1. Yamada Y, Higuchi K, Nishikawa K. et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 2015; 26(1): 141–148.
    1. Kang YK, Kang WK, Shin DB. et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20(4): 666–673.
    1. Cunningham D, Starling N, Rao S. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358(1): 36–46.
    1. Irino T, Takeuchi H, Terashima M. et al. Gastric cancer in Asia: unique features and management. Am Soc Clin Oncol Educ Book 2017; 37: 279–291.
    1. Kuo YC, Liu HT, Lin YL. et al. Modified biweekly oxaliplatin and capecitabine for advanced gastric cancer: a retrospective analysis from a medical center. Biomed J 2014; 37: 141–146.
    1. Shen L, Shan YS, Hu HM. et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol 2013; 14(12): e535–e547.
    1. Van Cutsem E, Moiseyenko VM, Tjulandin S. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24(31): 4991–4997.
    1. Bang YJ, Van Cutsem E, Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376(9742): 687–697.
    1. Fuchs CS, Tomasek J, Yong CJ. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383(9911): 31–39.
    1. Wilke H, Muro K, Van Cutsem E. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15(11): 1224–1235.
    1. Kang YK, Boku N, Satoh T. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390(10111): 2461–2471.
    1. Fuchs CS, Shitara K, Di Bartolomeo M. et al. RAINFALL: a randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. J Clin Oncol 2018; 36(Suppl 4): 5.
    1. Zou W, Wolchok JD, Chen L.. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 2016; 8(328): 328rv4.
    1. Geng Y, Wang H, Lu C. et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol 2015; 20(2): 273–281.
    1. Borghaei H, Paz-Ares L, Horn L. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373(17): 1627–1639.
    1. Brahmer J, Reckamp KL, Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373(2): 123–135.
    1. Ferris RL, Blumenschein G Jr, Fayette J. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375(19): 1856–1867.
    1. Motzer RJ, Escudier B, McDermott DF. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19): 1803–1813.
    1. Larkin J, Chiarion-Sileni V, Gonzalez R. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1): 23–34.
    1. Janjigian YY, Bendell J, Calvo E. et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 2018; 36(28): 2836–2844.
    1. Hato SV, Khong A, de Vries IJ, Lesterhuis WJ.. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Can Res 2014; 20(11): 2831–2837.
    1. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G.. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8(1): 59–73.
    1. Rizvi NA, Hellmann MD, Brahmer JR. et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016; 34(25): 2969–2979.
    1. NIH NCI Division of Cancer Treatment and Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE) Version 5, 2017; (16 November 2018, date last accessed).
    1. Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228–247.
    1. Teysuno (S-1) Summary of Product Characteristics; (16 November 2018, date last accessed).
    1. ELOXATIN (oxaliplatin) Prescribing Information; (16 November 2018, date last accessed).
    1. XELODA (capecitabine) Prescribing Information; (16 November 2018, date last accessed).
    1. Fuchs CS, Doi T, Jang RW. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018; 4(5): e180013.
    1. Kim GM, Jeung HC, Rha SY. et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012; 48(4): 518–526.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する